Lhasa Limited shared knowledge shared progress
Loading...
PublicationsJump to results
Authors
Publication Type
Publication Year
Related event
Related Products
Reset
TitlePublishedTypeProducts
ICH M7 Classification WorkflowMarch 2017pdf fileDerek NexusSarah Nexus
ICH M7 How Lhasa can support you.pdfMarch 2014pdf fileDerek Nexus
ICH M7 Overview: Predicting, Assessing, and Controlling Mutagenic Impurities from DegradationJune 2018pdf file
ICH M7 Use CasesJune 2018pdf fileDerek NexusSarah Nexus
ICH M7 Workflow.pdfNovember 2015pdf fileDerek NexusSarah NexusVitic Nexus
ICH Q3D: Practical implementation and the role of excipient data in a risk based approachDecember 2016
ICH Quality Guidelines: An Implementation GuideOctober 2017
Identification of Adverse Outcome Pathways for the Nephrotoxicity of Nucleoside and Nucleotide Anti-Viral DrugsMarch 2014pdf fileDerek Nexus
Impact from the Recent Issuance of ANVISA Resolution RDC-53/2015 on Pharmaceutical Small Molecule Forced Degradation Study RequirementsMay 2016Zeneth
Implementation of ICH M7 Recommended (Q)SAR AnalysesMarch 2016pdf fileDerek NexusSarah NexusVitic NexusZeneth
Importance of Comprehensive Reporting of (Q)SAR Assessments Under ICH M7.pdfMarch 2015pdf file
Important Considerations When Building Statistical-based Mutagenicity Models.pdfNovember 2015pdf fileSarah Nexus
Improvements to in silico mutagenicity predictivity of aromatic amines with access to proprietary dataMarch 2016pdf fileDerek Nexus
Improvements to in silico predictivity after access to proprietary dataApril 2016Derek Nexus
Improvements to In Silico Skin Sensitization Predictivity After Access to Proprietary DataMarch 2016pdf fileDerek Nexus
Improving Chemical Space Coverage of an In Silico Prediction System by Targeted Inclusion of Fragments Absent from the Training SetSeptember 2017pdf fileIntermediatesSarah NexusVitic Nexus
Improving Toxicity Predictions through knowledge and data sharingJune 2018pdf fileDerek NexusExcipientsIntermediatesiPiEVitic Nexus
Improving xenobiotic metabolite rankingNovember 2015Meteor Nexus
In Silico Analysis Of A Human Cardiac Adverse Effects Data Set.pdfJune 2010pdf fileDerek Nexus
In silico approaches to knowledge and data sharingOctober 2015pdf fileDerek NexusSarah Nexus
In Silico Drug Degradation Assessment in Early Phase DevelopmentMarch 2016pdf fileZeneth
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry surveyApril 2012
In Silico Prediction of Biotransformation Pathways - Decarboxylation of Aliphatic and Aromatic CompoundsSeptember 2010pdf fileMeteor Nexus
In Silico Prediction of Biotransformation Pathways: Amines and Related Compounds that Generate Isocyanates and Nitrile OxidesOctober 2009pdf fileMeteor Nexus
In Silico Prediction of Biotransformation Pathways: Furans and Thiophenes that Generate Epoxides, Aldehydes and S-OxidesOctober 2009pdf fileMeteor Nexus

© 2018 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.